MGNX - MacroGenics phase 1 prostate cancer asset data leads to phase 2 initiation later in 2023
- MacroGenics ( NASDAQ: MGNX ) will initiate a phase 2 trial of its biologic lorigerlimab later this year after preliminary phase 1 data showed promising results in metastatic castration-resistant prostate cancer (mCRPC).
- Results showed that nine of 35 patients -- ~26% -- with measurable mCRPC saw confirmed partial responses.
- About 29% of those in the mCRPC cohort achieved ? 50% prostate-specific antigen ("PSA") reduction.
- The data will be included in a poster presentation at the American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancers Symposium from Feb. 16-18.
- Check out why Seeking Alpha contributor Out of Ignorance rates MacroGenics ( MGNX ) a hold.
For further details see:
MacroGenics phase 1 prostate cancer asset data leads to phase 2 initiation later in 2023